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BACKGROUND
Asthma is the commonest long-term condition in children,
affecting an estimated five million schoolchildren in Europe.1
The condition is responsible for substantial morbidity with 11% of
children in the United Kingdom describing recurrent episodes of
wheeze,2 and resulting in days lost from school and time lost from
work for their parents/carers.3 Although in the United Kingdom,
most school-age children with asthma are managed in primary
care, each year there are in excess of 25,000 hospital admissions
for children under the age of 14 years.4 Of the 195 asthma deaths
investigated by the National Review of Asthma Deaths, 10 were in
children under the age of 10 years.4
The American Thoracic Society/European Respiratory Society
Task Force defines exacerbations (or asthma ‘attacks’) as events
characterised by a change from the patient’s previous status, which
may be severe (necessitating urgent action such as a course of
steroids and/or hospitalisation) or moderate (prompting a tempor-
ary change of treatment).5 Many definitions include a fall in peak
flow (e.g., to 50% or 75% of the patient’s best) though this may not
be helpful in younger children or those unfamiliar with undertaking
the manoeuvre,6 and may be indicative of poor asthma control
rather than exacerbation.7 Frequent exacerbations in children not
only have an impact on quality of life and school attendance but
are also associated with an accelerated loss of lung function.8,9
Guidelines highlight that monitoring should not only include
objective assessment of symptomatic asthma control with validated
questionnaires (e.g., Asthma Control Questionnaire10,11 or Asthma
Control Test12,13) or morbidity scores (e.g., Royal College of
Physicians three questions14) but also include an assessment of
the future risk of an exacerbation. Although recent work has
devised a risk score for use in adults (16–60 years), with an area
under the receiver operating characteristic curve for prednisolone
use of 0.83,15 no such score exists for children aged 5–12 years.
A recent previous history of exacerbations, in particular, severe
exacerbations,16–21 and persistent poor control20,21 are strongly
associated with an increased risk of severe exacerbations, but
many other predictors have been described in children and young
people. Allergic sensitisation,16,18,22–24 seasonal variability,17,19
exposure to environmental tobacco smoke,18,25 no inhaled
steroids17,20,21 regimes with multiple inhalers,26 impaired lung
function16,20 and poor adherence to preventer medication27 have
all been associated with increased risk of exacerbations. Other
factors described in adults and teenagers (such as socioeconomic
status,28 ethnicity,29 upper airways disease,30 blood eosinophilia,31
obesity32,33 and non-attendance for review appointments4)
may also be relevant as predictors of exacerbations in young
children. There is thus a need to identify and weight risk factors in
children aged 5–12 years from factors identified in a systematic
review, which can be further tested and validated in this
population group.
The focus of this systematic review will be factors that increase a
child’s propensity to asthma exacerbations, rather than immediate
triggers for exacerbations, e.g., respiratory tract infections, exposure
to airborne pollutants or allergens, physical or emotional exertion.
AIMS
To undertake a systematic review of the literature to:
1. Identify factors associated with the risk of asthma exacerba-
tions in children aged 5–12 years.
2. Quantify their importance to inform the assessment of risk in
children.
METHODS
We will follow the systematic review procedures described in the
Cochrane Handbook for Systematic Reviews of Interventions.34
‘PICOS’ criteria
The PICOS criteria and study designs of interest are given in
Table 1. We will include both controlled trials of interventions that
aim to reduce exacerbation risk and observational studies, which
seek to identify risk factors. We are interested in factors that
contribute to future risk as opposed to immediate triggers (such as
contracting an upper respiratory tract infection, or events such as
thunderstorms). We will not include trials of pharmacological
efficacy, or studies of unusual events or factors that cannot be
routinely measured/tested or those that are not routinely
available. Studies investigating risk factors for incidence/
prevalence of asthma, asthma symptoms or objective measures
of asthma activity (lung function, symptom scores, medication
usage, health care utilisation) will not be included.
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Outcome measures
Our primary outcome will be severe exacerbations of asthma:
asthma symptoms and/or objective evidence of airways obstruction
outside the patients’ normal variation necessitating (a) a short course
(at least 3 days) of oral corticosteroids and/or (b) a hospitalisation or
emergency department visit requiring systemic corticosteroids.5
In addition, we are interested in risk factors for, and predictors
of moderate exacerbations.5 See Table 1 for definitions.
Identification of studies
The following electronic databases will be searched: MEDLINE,
EMBASE, CINAHL, AMED, PsycINFO and CENTRAL. Unpublished and
in-progress studies will be identified by the following: (a) searching
internet-based trial registries, i.e., ClinicalTrials.gov (http://www.
clinicaltrials.gov) and Current Controlled Trials (www.controlled-
trials.com), and (b) contacting experts in the field. See Appendix 1
for an example of the search strategy developed for the MEDLINE
database that will be adapted to search other databases. Papers
included in related systematic reviews in adults will be checked to
identify reports on children,35 and forward and backward citation
checks will be undertaken on the included papers. In addition, our
expert advisors will be asked to identify known and anticipated
risk factors for asthma exacerbations in children as a reality check
to ensure we have captured all likely predictors.
No language or publication time restrictions will be imposed.
Translations will be undertaken where necessary, and papers for
which translation is not feasible will be noted.
Study selection and data extraction
Independently, two reviewers (NT or Audrey Buelo (AB) and SMcL)
will perform the following:
● Review titles and abstracts of papers identified from the
literature searches and select potentially relevant studies.
● Assess retrieved full texts of all potentially eligible studies
against the review inclusion/exclusion criteria.
● Extract data using a customised data extraction form, piloted on
a subsample to ensure the form is easily and consistently
interpreted and captures all relevant information (including
PICOS criteria, definitions used and outcomes).
Disagreements at each stage of the review will be resolved by
discussion between the reviewers (NT/AB and SMcL) or, if
necessary, arbitration by a third reviewer (HP). Unresolved issues
relating to interpretation of inclusion/exclusion criteria will be
referred to the Steering Group.
We will attempt to contact authors of the papers with missing
or unclear essential information. Multiple publications from the
same study will be treated as a single study, but draw on all the
relevant publications.
The selection process will be summarised using a PRISMA flow
diagram.36
Assessment of the methodological quality
Two reviewers (AB and SMcL) will independently assess the
methodological quality of the included papers. Using the
Cochrane Risk of Bias Tool,34 randomised trials will be assessed
for bias. Each individual domain (selection, performance, detec-
tion, attrition, reporting and other bias) will independently be
judged by two reviewers (AB and SMcL) to be at low, unclear or
high risk of bias. A summary assessment will include the overall
risk of bias. Non-randomised studies will be assessed using the
Newcastle-Ottawa checklist,37 which covers selection, compar-
ability and outcome domains and is customised for cross-
sectional, case–control and cohort studies. Authors will be
contacted for unpublished information.38
Data analysis and synthesis
We will provide a descriptive summary of the factors associated
with a significant risk of exacerbation of asthma in children aged
5–12 years in detailed tables, and undertake a narrative synthesis
of the data. We anticipate substantial heterogeneity of the studies
and so do not plan to undertake a formal quantitative meta-
Table 1. PICOS criteria for the search strategy
Population Children aged 5–12 years with doctor-diagnosed ‘active’ asthma (that is who have had a prescription for
asthma treatment within the previous year), across all severities and degrees of control. We will include studies
with a wider range of ages if results for children aged 5–12 years are reported separately or if 450% of the
children are within this age range.
Intervention (if applicable) Any intervention that aims to reduce exacerbation risk, specifically excluding trials of pharmacological efficacy
as robust reviews are in existence for these. Examples might include interventions to improve medication-
related behaviour (adherence, inhaler technique), social or lifestyle adaptation, improve residential
environment (reduce housing damp/mould, improve indoor air quality) and reduce stress in mothers and
children). Observational studies (cohort, case–control and cross-sectional) without a specific intervention that
seek to identify relevant risk factors will also be included.
Control/comparator (if applicable) Usual care.
Outcomes Our primary outcome is severe exacerbations of asthma defined according to the ATS/ERS Task Force: asthma
symptoms and/or objective evidence of obstruction outside the normal variation for the patient necessitating
(a) a short course (at least 3 days) of oral corticosteroids and/or (b) a hospitalisation or emergency department
visit requiring systemic corticosteroids.5
Moderate exacerbations as defined by the ATS/ERS task force (asthma symptoms and/or airflow obstruction)
outside the normal variation for the patient prompting a temporary change of treatment (excluding systemic
steroids) to prevent a severe exacerbation.5
Setting Any setting
Study designs Randomised controlled trials, controlled clinical trials, interrupted time series, controlled before-and-after
studies, cohort and case-controlled studies (but not case studies or case series).
Abbreviation: ATS/ERS, American Thoracic Society/European Respiratory Society.
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analysis, but will weight identified factors as conferring slightly,
moderately or greatly increased risk, based on the observed effect
size and confidence intervals and the quality of the included
papers, which will be interpreted in the light of biological
plausibility. The weighting will be done independently by two
raters. Disagreements will be resolved by discussion with a third
rater arbitrating if necessary
The results across studies will be explored graphically and
through summary measures to investigate whether the hetero-
geneity of effect can be accounted for by known factors. Severity
of asthma and co-morbid rhinitis are part of the causal pathway
for the outcome and are likely to be predictors in the final model
and so will be investigated in an exploratory way.
The protocol is registered with PROSPERO International
Prospective Register of Systematic Reviews (CRD42016037464),
and the findings will be summarised and published in a peer-
reviewed journal.
DISCUSSION
The key aim of the management of asthma in children (and all
ages) is to reduce the burden of disease both by achieving good
control of day-to-day symptoms and by reducing the risk of
troublesome, and potentially serious asthma attacks. Targeting
those at risk, has the potential to facilitate care commensurate
with need and improve outcomes for those at highest risk.
Likely risk factors include markers of severe disease and historical
poor control (including previous exacerbations), as well as allergic
sensitisation, exposure to environmental factors (including
parental smoking), especially, the combination of infection and
allergen exposure in sensitised children,24 and poor adherence
to preventer medication and non-attendance for review
appointments. Identification and weighting of these features of
children and their family/environment will allow clinicians to
identify ‘at-risk’ children, and inform discussions with parents
about the need for regular ‘preventer’ treatment.
The vision is that risk assessment will have application both
clinically for assessing individual children’s asthma control and
thus focussing additional care on those at high risk, as well as
for assessing control within populations and targeting care at
high-risk populations.
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APPENDIX 1
Ovid MEDLINE(R) 1946 to present with daily update—executed 10 May 2016
# Search statement Results
1 exp Asthma/ or Bronchial Spasm/ or exp Bronchoconstriction/ or (asthma* or wheez* or bronchoconstrict* or bronchial constrict* or bronch* constrict* or bronchial
spasm or bronchospas*or bronch* spasm*).tw.
150958
2 Bronchial Hyperreactivity/ or Respiratory Hypersensitivity/ 15662
3 1 or 2 157160
4 (exacerb* or deteriorat* or aggravate* or acute* or status* or sever* or wors* or attack* or crisis or critical or hospital* or relapse or uncontrolled or poor* controlled).tw.
or exp Recurrence/ or exp Disease Progression/ or exp Mortality/ or exp Death/
4817367
5 exp Emergency Service, Hospital/ or exp Emergency Medical Services/ or exp Hospitalisation/ or exp Hospitals/ or exp Intensive Care Units/ or exp Emergencies/ or
(emergenc* or acute care or intensive care or intensive treatment unit* or hospital*).tw.
1291812
6 (admission* or admit* or attend* or visit* or present* or utilis* or utiliz* or use* or using).tw. 8649008
7 5 and 6 708396
8 exp Primary Health Care/ or exp General Practice/ or exp Family Practice/ or exp Physicians/ or (physician* or doctor* or health care professional or general practice or
asthma nurse or specialist nurse or GP).tw.
574496
9 exp ‘Appointments and Schedules’/ or appointment*.tw. or visit*.tw. 165155
10 (unscheduled or additional or increase*).tw. 3829910
11 8 and 9 and 10 9990
12 exp Medicine/ or exp Therapeutics/ or exp Anti-Asthmatic Agents/ or exp Bronchodilator Agents/ or exp Adrenergic beta-Agonists/ or exp Cholinergic Antagonists/ or
exp Steroids/ or exp Glucocorticoids/ or (medicin* or treatment or medication or steroid* or corticosteroid* or glucocorticosteroid* or inhaler* or beta agonist* or beta-
2-agonist* or SABA or anticholinergic* or ICS).tw.
7354258
13 (rescue or supplement* or (step* adj up) or adjuvant or additional or increase*or augment*).tw. 849246
14 12 and 13 379948
15 exp Steroids/ or exp Glucocorticoids/ or (steroid* or corticosteroid* or glucocorticosteroid*).tw. 923905
16 (systemic or oral or intravenous or intramuscular or injectable or parenteral or IV or IM).tw. or exp Injections, Intravenous/ or exp Administration, Intravenous/ or exp
Injections, Intramuscular/ or exp Infusions, Parenteral/ or rescue.tw.
1384151
17 15 and 16 120669
18 (((nocturnal or night* or sleep*) adj2 (symptom* or wheeze* or asthma or wakening or woken or disturb*)) or ((daily or daytime) adj2 (activit* adj2 disturb*))).tw. 15029
19 exp Oxygen Inhalation Therapy/ or exp Intubation, Intratracheal/ or nebuli*.tw. 63956
20 ((increas* or wors* or aggravate*) and (frequenc* or sever* or symptom* or wheez* or breathless* or dyspn?a)).tw. 870900
21 4 or 7 or 11 or 14 or 17 or 18 or 19 or 20 5466020
22 3 and 21 67554
23 Risk Factors/ or Risk/ or (risk adj3 factor*).tw. or predict*.tw. or (risk* adj2 exacerb*).tw. 1719001
24 23 and 22 12770
25 Animals/ not Humans/ 4196538
26 24 not 25 12662
27 Adult/ not Child/ 3672244
28 26 not 27 8379
29 (COPD.tw. or Pulmonary Disease, Chronic Obstructive/) not Asthma/ 31916
30 28 not 29 8099
31 Comment/ or Letter/ or Editorial/ or Autobiography/ or Biography/ or Bibliography/ or Dictionary/ or Directory/ or Interactive Tutorial/ or Lectures/ 1578832
32 30 not 31 7989
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